In previous investigations, oral administration of FXR antagonist, T-β-MCA derivative or glycine-β-MCA, was found to decrease murine FXR signals in the ileum, that resulted in improvement of insulin resistance, obesity and liver steatosis associated with lower level of serum ceramide levels 18. The gene discussed is NR1H4; the disease is obesity disorder.